Plath T, Dallenbach F
Klinik für Kieferchirurgie und Plastische Gesichtschirurgie, Klinikum Benjamin Franklin, Freie Universität Berlin.
Mund Kiefer Gesichtschir. 1998 Sep;2(5):275-8. doi: 10.1007/s100060050074.
Basal cell adenocarcinoma was first introduced as an entity in the second edition of the WHO's "Histologic Typing of Salivary Gland Tumours" in 1991. This tumor was first described in 1990 by Ellis and Wiskovitch from the Armed Forces Institute of Pathology (AFIP). Basal cell adenocarcinoma accounts for about 2.9% of all salivary gland malignancies. More than 90% of the tumors are situated in the parotid gland. Intraoral manifestations are known from case reports only. Tumors of the palate have been mentioned in three cases. Histologically this tumor can be easily confused with basal cell adenoma and the solid basaloid subtype of adenoid cystic carcinoma. The case presented here is a middle-aged white woman with a basal cell adenocarcinoma of the palate. Therapy consisted of surgical extirpation with three-dimensional safety margins and histologically proven clear resection margins. Knowledge at this point indicates that basal cell adenocarcinoma has a rather high probability of local recurrence (up to 50%) and a mostly lymphogenous metastatic potential for as long as 10 years after removal of the primary tumor. Ten year survival is around 75%.
基底细胞腺癌于1991年在世界卫生组织《涎腺肿瘤组织学类型》第二版中首次作为一种独立的肿瘤类型被提出。该肿瘤于1990年由武装部队病理研究所(AFIP)的埃利斯和维斯科维奇首次描述。基底细胞腺癌约占所有涎腺恶性肿瘤的2.9%。超过90%的肿瘤位于腮腺。口腔内表现仅见于病例报告。腭部肿瘤在三例病例中被提及。在组织学上,这种肿瘤很容易与基底细胞腺瘤和腺样囊性癌的实性基底样亚型混淆。本文报道的病例是一名患有腭部基底细胞腺癌的中年白人女性。治疗方法为进行三维安全切缘的手术切除,且组织学证实切缘阴性。目前的知识表明,基底细胞腺癌局部复发的概率相当高(高达50%),并且在原发肿瘤切除后长达10年的时间里大多具有淋巴源性转移潜能。十年生存率约为75%。